0000000000368483

AUTHOR

K. Wiedemann

showing 3 related works from this author

Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patien…

1991

The new tetracyclic compound savoxepine exhibits potent antidopaminergic effects with preferential activity in the hippocampus as compared to striatum in rat brain. As a result of behavioural animal models and regional differences in dopamine receptor binding characteristics, it has been suggested to possess an "atypical" neuroleptic response pattern. In an open clinical trial, savoxepine was administered to 12 in-patients suffering from paranoid schizophrenia and schizophreniform disorder (DSM-III). Eight patients were treated with a stable dose of 0.5 mg per day throughout the study, while in the remaining patients higher doses up to 20 mg/day were administered. Mean total BPRS scores and…

AdultMalePsychosisParanoid schizophreniamedicine.medical_treatmentPharmacologyExtrapyramidal symptomsBasal Ganglia DiseasesmedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesDopamine antagonistDopamine receptor bindingMiddle Agedmedicine.diseaseEnzymesDisease Models AnimalSchizophreniaDibenzoxazepinesSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologymedicine.drugAntipsychotic AgentsPsychopharmacology
researchProduct

Formation and metabolism of catecholestrogens in depressed patients.

1990

Abstract The evidence that catecholestrogens are formed in the brain and exert behavioral effects in animal models suggests that these steroids might have psychotropic activities. In the present investigation, the formation and metabolism of catecholestrogens were studied in depressed patients. Twenty-four-hr urine samples were collected from 6 male patients (59 ± 8 years) with endogenous retarded depression (subtype primary, endogenous, and recurrent according to Research Diagnostic Criteria) and from 12 male control subjects (51 ± 4 years). The patients were treated with the monoamine oxidase inhibitor tranylcypromine (10–40 mg/day for 3–4 weeks). The concentrations of primary estrogens, …

Malemedicine.medical_specialtyMonoamine oxidase inhibitorDepressive Disordermedicine.drug_classTranylcypromineEndogenyRadioimmunoassayEstrogensMetabolismUrineBiologyMiddle AgedEstrogens CatecholExcretionEndocrinologyInternal medicinemedicineHumansTranylcypromineBiological PsychiatryDepression (differential diagnoses)medicine.drugBiological psychiatry
researchProduct

Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppressi…

1987

AdultMalemedicine.medical_specialtyDepressive DisorderHypothalamo-Hypophyseal SystemBipolar DisorderHydrocortisonebusiness.industryCorticotropin-Releasing HormonePituitary-Adrenal SystemMiddle AgedPathophysiologyDexamethasoneCorticotropin-releasing hormoneEndocrinologyAdrenocorticotropic HormoneInternal medicinemedicineHumansFemalebusinessBiological PsychiatryDepression (differential diagnoses)Dexamethasonemedicine.drugBiological psychiatry
researchProduct